|
|
 |
|
Viewing report
|
|
|
|
The Outlook for Pharmaceuticals in South East Asia to 2013
Espicom Business Intelligence Ltd, Sep 2009
The eight Asian countries covered in this service represented a total market of 588 million people and a combined GDP of US$2.8 trillion in 2008
Business opportunities in Asian pharmaceutical markets are very different from a few years ago. The traditional tiger economies, characterised by economic growth, free market environment, developed industry and investment in health and health infrastructure have had a long haul back from the financial instability and economic downturn in the 1990’s.
Tiger Cubs?
At the same time, markets that had hitherto excited little industry or investor interest, have emerged as real areas of opportunity for suppliers and service companies alike. Diverse influences - from deregulation and better trade links to improved access and the rise of medical tourism - are seeing markets such as Malaysia and Vietnam take an increasingly important role in the region.
Sustained growth
With established western markets maturing, serious attention is being paid to the countries where manufacturers can see significant long-term growth. However, effective planning is vital, and impartial, thoroughly researched business data is essential to fully appreciate the current market status as a basis for future development.
These quarterly updated reports analyse the issues
That is why Espicom Business Intelligence has published these new management reports The Outlook for Pharmaceuticals in South East Asia to 2013. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually or as a discounted collection, and prices include 4 completely updated reports sent quarterly plus a comprehensive annual review.
Executive Summary
8 Markets Covered!
Indonesia Philippines South Korea Thailand
Malaysia Singapore Taiwan Vietnam
Highlights from the report
INDONESIA
The Indonesian market for pharmaceuticals was valued at US$1.9 billion in 2008, equal to just under US$7 per capita. In overall terms, the market is similar in size to that of Egypt or Colombia, whereas in per capita terms, the total is similar to that of Pakistan or Vietnam. Indonesia spends an estimated 16.1% of its total health expenditure on pharmaceuticals, and around 0.4% if total GDP. The domestic pharmaceutical manufacturing industry is strong and the country has become an attractive base for many multinational producers to operate. This is largely down to a cheap labour force and generally inexpensive production costs.
MALAYSIA
Espicom estimates current growth in the market to be 11.1% per year. This would see the market surpass the US$1 billion mark by 2009, and reach US$1.4 billion by 2012, or US$47 per capita. Having weathered the aftermath of the 1998 economic crash better than most, market growth accelerated considerably in the following years, as imports in particular continued to increase and dominate the market.
PHILIPPINES
Changes to be brought by the controversial Cheaper Medicine Bill will impact the Philippines pharmaceutical market in a number of areas, including IP laws, competition and drug price control mechanisms. The market is expected to be especially volatile in the 2008-2010 period. The Philippines pharmaceutical market is valued at US$1.4 billion in 2008, equal to nearly US$15 per capita. In terms of the overall market this is comparable to Pakistan and Thailand, and in per capita terms similar to China and Iran.
SINGAPORE
Espicom estimates the Singaporean market to exhibit annual average growth of around 4%, with impressive economic indicators being tempered by the limited population size. Based on this rate, it is estimated the market will reach US$809 million by 2012, equal to US$176 per capita. The manufacture of pharmaceuticals is dominated by multinational companies and the government has indicated that it wants at least ten multinational manufacturing facilities operational in Singapore by 2010.
SOUTH KOREA
The Korean pharmaceutical market is the largest of all the ‘Asian Tigers’ by some considerable distance, one of the twenty largest in the world and is similar in size to that of Brazil and India. In per capita terms, the market is comparable to fellow ‘Tiger’ nations, Singapore and Taiwan. Intellectual property protection, long regarded as being insufficient, is likely to improve with the Free Trade Agreement (FTA) signed with the US in 2007, with an improved patent linkage system to be implemented by 2009.
TAIWAN
Taiwan is a difficult, but attractive market with strong fundamentals. Taiwan’s healthy economy, steadying currency and growing imports of pharmaceuticals should see the pharma market surpass the US$6 billion mark by 2012. There is a heavy multinational presence - over 70% of the market is controlled by overseas multinationals. Over 100 generic drug manufacturers currently operate in Taiwan. An opaque regulatory process and discriminatory reimbursement practices exist and legislation to bring the country more in line with international standards has been announced, but so far, little has changed.
THAILAND
While import levels for modern drugs are approaching levels last seen before the economic recession, the Thai market is heavily reliant on generics. The government's relationship with the international pharmaceutical industry continues to be uneasy, largely due to the country's lax patent laws and preferential treatment of domestic producers. The compulsory licensing of drugs by the government has further compounded this problem.
VIETNAM
The pharmaceutical market is expected to expand slowly in Vietnam over the next few years. The government hopes to boost per capita spending to US$10-15 by 2010, through a major development programme, although this figure looks ambitious. Opportunities exist within the Vietnamese market in terms of specialist pharmaceutical production. The country’s accession into the WTO in January 2007 is expected to further open up the market and make it more attractive to investors. ..... FOR EVERY MARKET,
SENT QUARTERLY
MARKET OUTLOOK
Current market size
Unique 5-Year market projections to 2013
Market outlook
Comment & rating, covering 8 key areas such as use of generic drugs, intellectual property, pricing and the health systems
Market structure
Statistical data on imports and exports
Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, funding and
government policy
Key national data projections
FOR EVERY MARKET,
SENT ANNUALLY
BACKGROUND DATA
Population data, including growth trends and age structure
Demographic indicators detailing principal causes of death and morbidity
HEALTHCARE SYSTEM
Organisation & administration
Health expenditure
- Expenditure by source of funding and type
Hospital services
- Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures
Outpatient care
Medical personnel
- Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists
ACCESSING THE PHARMA MARKET
Regulatory environment
Distribution guide and trade fair information
Domestic production
CONTACT DETAILS
Healthcare organisations
Trade associations
Customers who bought this item also bought
The Pharmaceutical Market: Vietnam
The Pharmaceutical Market: Singapore
The Outlook for Pharmaceuticals in Central Asia
The Pharmaceutical Market: Philippines
The Outlook for Pharmaceuticals in Central & Eastern Europe to 2013
The Pharmaceutical Market: South Korea
The Outlook for Pharmaceuticals in Northern Europe to 2013
The Outlook for Pharmaceuticals in Latin America to 2013
The Pharmaceutical Market: Taiwan
The Pharmaceutical Market: Sweden
Vietnam Pharmaceuticals and Healthcare Report Q1 2009
The Pharmaceutical Market: Indonesia
|
|
|
|
